💡 Renewal of EU-GMP certification for flagship biologics manufacturing facility maintains European market access.
What Happened
Onesource Specialty Pharma Limited has successfully received renewal of the European Union Good Manufacturing Practices (EU-GMP) certification for its flagship Unit II manufacturing facility in Bengaluru. The renewal follows an inspection conducted by a European regulatory authority. Unit II is an integrated biologics drug-substance and drug-product manufacturing site with capabilities in drug-device combinations and sterile injectable products.
Key Details
- Company: Onesource Specialty Pharma Limited
- Event Type: Regulatory
- Filing Date: 17-Apr-2026 19:38:31
- NSE Filing: View Document
Why It Matters
The renewal of EU-GMP certification is crucial for pharmaceutical companies exporting to European markets, as it validates compliance with stringent quality standards required by European regulators. This certification allows Onesource Specialty Pharma to continue manufacturing and supplying sterile injectable biologics products to European customers without disruption. Maintaining this certification supports the company's position as a contract development and manufacturing organization (CDMO) serving global pharmaceutical markets and demonstrates ongoing regulatory compliance at their flagship facility.
Disclaimer: This is publicly available information sourced from NSE. Not investment advice.
Get signals like this instantly
Free Telegram alerts within 2 minutes of NSE filing
Join SuperStock Free